Insider Transactions in Q4 2021 at Myriad Genetics Inc (MYGN)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 08
2021
|
Nicole Lambert Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+5.42%
|
-
|
|
Nov 30
2021
|
Jayne B. Hart Officer |
BUY
Grant, award, or other acquisition
|
Direct |
143
+0.1%
|
$3,003
$21.98 P/Share
|
|
Oct 18
2021
|
Pamela Wong Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,753
+50.0%
|
-
|
|
Oct 09
2021
|
Kevin Richard Haas Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,729
-3.15%
|
$51,870
$30.88 P/Share
|
|
Oct 09
2021
|
Jayne B. Hart Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,926
-1.64%
|
$147,780
$30.88 P/Share
|
|
Oct 09
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,483
-3.6%
|
$374,490
$30.88 P/Share
|
|
Oct 09
2021
|
Jerry S Lanchbury Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,811
-1.98%
|
$324,330
$30.88 P/Share
|
|
Oct 09
2021
|
Richard Bryan Riggsbee Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,398
-1.69%
|
$371,940
$30.88 P/Share
|
|
Oct 09
2021
|
Mark Verratti Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,340
-2.08%
|
$250,200
$30.88 P/Share
|
|
Oct 01
2021
|
Nicole Lambert Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,420
-0.8%
|
$44,020
$31.57 P/Share
|